FindTrial
Sign In

Interactive network platform improves patient compliance and efficacy of subcutaneous immunotherapy in the treatment of patients with allergic rhinitis

Interactive network platform improves patient compliance and efficacy of subcutaneous immunotherapy in the treatment of patients with allergic rhinitis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900026489
Enrollment
Unknown
Registered
2019-10-12
Start date
2019-10-15
Completion date
Unknown
Last updated
2019-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergic rhinitis

Interventions

Experimental group:Interactive network platform
Control group:Standardized management

Sponsors

Third Xiangya Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 43 Years

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years; 2. Meet the SCIT guidelines and the physician's assessment and without any contraindications for SCIT; 3. Be proficient in using smartphones and had a smartphone.

Exclusion criteria

Exclusion criteria: 1. to be experienced a severe systemic reaction (rapid onset (<15 minutes), widespread urticaria, angioedema or severe asthma) or anaphylactic shock of unknown origin during treatment; 2. participating in other projects related to SCTI management; 3. With other serious physical or psychological conditions, such as cancer, chronic kidney failure, schizophrenia, and autism.

Design outcomes

Primary

MeasureTime frame
compliance;—

Secondary

MeasureTime frame
VAS;CSMS;Rhinoconjunctivitis Quality of Life Questionnaire;—

Countries

China

Contacts

Public ContactTan Guolin

Third Xiangya Hospital, Central South University

guolintan@csu.edu.cn+86 0731-88618024

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026